A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 18 Aug 2017 Planned End Date changed from 1 Aug 2019 to 1 Jun 2019.
    • 18 Aug 2017 Planned primary completion date changed from 1 Jul 2019 to 1 May 2019.
    • 07 Jul 2017 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top